Can a heart drug tame blood sugar and weight in diabetes?

NCT ID NCT06423729

Completed Disease control Sponsor: Tanta University Source: ClinicalTrials.gov ↗

First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether adding nicorandil, a drug typically used for heart conditions, can improve blood sugar control and reduce body weight in obese people with type 2 diabetes who are already taking sulfonylureas. About 46 adults with a BMI over 30 will receive nicorandil 10 mg twice daily for 3 months. Researchers will measure changes in HbA1c, body weight, BMI, and markers of inflammation and blood vessel health.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Nicorandil 10 mg oral tablets taken twice daily for 3 months
What this could lead to: If effective, nicorandil could become an add-on treatment to improve blood sugar control and support weight management in obese people with type 2 diabetes.
What could go wrong: This is a small, early-phase trial, so results may not apply broadly. Nicorandil can cause side effects like headaches and low blood pressure, and its benefits are not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES MELLITUS, TYPE 2

Contacts and locations

Locations

Faculty of Pharmacy, Tanta University

Tanta, 31511, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.